What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab?

被引：2
|
作者：
Mehanna, Joe [1 ]
Haddad, Fady G. H. [2 ]
Eid, Roland [2 ]
Lambertini, Matteo [3 ,4 ,5 ]
Kourie, Hampig Raphael [2 ]
机构：
[1] St Joseph Univ, Fac Med, Beirut, Lebanon
[2] St Joseph Univ, Hematol Oncol Dept, Fac Med, Beirut, Lebanon
[3] Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium
[4] Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium
[5] Univ Libre Bruxelles, Blvd Waterloo 121, B-1000 Brussels, Belgium
来源：
TRANSLATIONAL CANCER RESEARCH | 2018年 / 7卷 / 06期
关键词：
ADJUVANT TRASTUZUMAB; SURVIVAL;
D O I：
10.21037/tcr.2018.09.07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1354 / 1356
页数：3
相关论文
共 50 条
  • [21] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
  • [22] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Mortimer, Joanne
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 662 - 663
  • [23] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [24] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [25] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [26] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [27] Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab
    Canale, Maria laura
    Casolo, Giancarlo
    Donati, Sara
    Bisceglia, Irma
    Puccetti, Cheti
    Amoroso, Domenico
    Venturini, Elio
    Maurea, Nicola
    Turazza, Fabio maria
    Camerini, Andrea
    IN VIVO, 2023, 37 (05): : 2139 - 2146
  • [28] Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman, AD
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (04): : 178 - 179
  • [29] Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Andrew D Seidman
    Nature Clinical Practice Oncology, 2006, 3 : 178 - 179
  • [30] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
12345